Patents by Inventor Tina Møller Tagmose

Tina Møller Tagmose has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11471537
    Abstract: This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to novel Fc fragments, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: October 18, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Tina Moeller Tagmose, Peter Madsen, Thomas Boerglum Kjeldsen, Lone Pridal, Leonardo De Maria, Zhaosheng Lin, Zhe Wan, Yuanyuan Zhang, Lennart Lykke, Martin Werner Borchsenius Muenzel, Janos Tibor Kodra
  • Publication number: 20210393745
    Abstract: This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to a novel Fc fragment, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.
    Type: Application
    Filed: October 9, 2019
    Publication date: December 23, 2021
    Inventors: Tina Moeller Tagmose, Peter Madsen, Thomas Boerglum Kjeldsen, Lone Pridal, Zhaosheng Lin, Yuanyuan Zhang, Zhe Wan
  • Publication number: 20200261595
    Abstract: This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to novel Fc fragments, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.
    Type: Application
    Filed: April 4, 2018
    Publication date: August 20, 2020
    Applicant: Novo Nordisk A/S
    Inventors: Tina Moeller Tagmose, Peter Madsen, Thomas Boerglum Kjeldsen, Lone Pridal, Leonardo De Maria, Zhaosheng Lin, Zhe Wan, Yuanyuan Zhang, Lennart Lykke, Martin Werner Borchsenius Muenzel, Janos Tibor Kodra
  • Publication number: 20190112348
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Application
    Filed: December 14, 2018
    Publication date: April 18, 2019
    Inventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Janos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • Patent number: 10259856
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: April 16, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Janos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • Patent number: 10124039
    Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: November 13, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
  • Publication number: 20180140673
    Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.
    Type: Application
    Filed: December 21, 2017
    Publication date: May 24, 2018
    Applicant: Novo Nordisk A/S
    Inventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
  • Patent number: 9896496
    Abstract: The present invention provides a novel derivative of an analogue of human insulin, useful for the treatment of diabetes.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: February 20, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Tina Moeller Tagmose, Helle Naver, Thomas Boerglum Kjeldsen
  • Patent number: 9895417
    Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: February 20, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
  • Publication number: 20170354713
    Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.
    Type: Application
    Filed: July 7, 2017
    Publication date: December 14, 2017
    Inventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
  • Patent number: 9744213
    Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: August 29, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
  • Publication number: 20170182124
    Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.
    Type: Application
    Filed: March 8, 2017
    Publication date: June 29, 2017
    Inventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
  • Patent number: 9688737
    Abstract: Novel acylated insulin analoges exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analoges contain B25H and A14E or A14H.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: June 27, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Thomas B. Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Janos Tibor Kodra
  • Patent number: 9655974
    Abstract: Analogs of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD).
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: May 23, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Tina Moeller Tagmose, Patrick William Garibay, Xujia Zhang, Henning Thoegersen, Peter Kresten Nielsen, Kristian Sass Bak-Jensen, Helle Fabricius Woeldike
  • Patent number: 9480753
    Abstract: The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: November 1, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Tina Møller Tagmose, Patrick William Garibay, Bírgítte Andersen, Henning Thøgersen, Birgit Wieczorek
  • Publication number: 20160215037
    Abstract: The present invention provides a novel derivative of an analogue of human insulin, useful for the treatment of diabetes.
    Type: Application
    Filed: October 3, 2014
    Publication date: July 28, 2016
    Inventors: Peter Madsen, Tina Moeller Tagmose, Helle Naver, Thomas Boerglum Kjeldsen
  • Patent number: 9260503
    Abstract: The present invention regards an insulin derivative comprising at least 2 albumin binding moieties, wherein said albumin binding moieties comprise fatty diacid substitutions and a method for preparing such an insulin derivative by acylation and/or reductive alkylation. The present invention also concern a pharmaceutical comprising such an insulin derivative.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: February 16, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Hoeg-Jensen, Peter Madsen, Jane Spetzler, Tina Moeller Tagmose
  • Patent number: 9242011
    Abstract: Insulin albumin conjugates consisting of an insulin analogue, a bifunctional linker and albumin can efficiently be used to treat diabetic patients.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: January 26, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Tina Møller Tagmose, Peter Madsen, Thomas Børglum Kjeldsen
  • Patent number: 9150633
    Abstract: An acylated insulin analogue wherein the insulin analogue comprises a lysine residue connected C-terminally to the A21 amino acid residue or a peptide residue of up to 4 amino acid residues comprising a lysine residue which peptide residue is connected C-terminally to the A21 amino acid residue, characterized in that an acyl moiety comprising an alkylene glycol moiety is attached to the lysine residue in the A22 position or attached to a lysine residue present in the peptide residue that is attached to the C terminal end of the A21 amino acid residue and wherein there is only one lysine (K, Lys) in the insulin analogue, can conveniently be administered pulmonary.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: October 6, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Thomas Børglum Kjeldsen, Thomas Hoeg-Jensen, Tina Møller Tagmose, Palle Jakobsen, János Tibor Kodra, Patrick William Garibay, Dorte Xenia Gram
  • Patent number: RE46170
    Abstract: The present invention relates to insulin derivatives having a side chain attached either to the ?-amino group of the N-terminal amino acid residue of the B chain or to the ?-amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which side chain comprises at least one aromatic group; at least one free carboxylic acid group or a group which is negatively charged at neutral pH, a fatty acid moiety with 4 to 22 carbon atoms in the carbon chain; and possible linkers which link the individual components in the side chain together via amide bonds.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: October 4, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Janos Tibor Kodra, Patrick William Garibay, Thomas Hoeg-Jensen, Ib Jonassen, Peter Madsen, Tina Moeller Tagmose